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The therapeutic approach towards extensive-stage 
small-cell lung cancer (SCLC) has remained unchanged 
for the last 20 years. Benefit from the standard systemic 
treatment (platinum-based chemotherapy doublet) is 
limited despite high response rates. Numerous attempts 
of expanding treatment with the addition of other 
agents have failed to improve the outcomes. As novel 
immunotherapeutic drugs revolutionised treatment 
standards in several types of cancer, attempts were 
made to introduce this modality into the treatment of 
SCLC. Unfortunately, the results obtained from trials 
evaluating the combination of standard chemotherapy 
with CTLA-4 inhibitors and pembrolizumab mainte-
nance after chemotherapy induction were negative. It 
is more than disappointing considering the high tumour 
mutational burden (TMB) often present in SCLC, 
which is proposed as a predictive marker for checkpoint 
inhibitors. Fortunately, recent data have proven that 
a PD-L1 inhibitor, atezolizumab, improves overall sur-
vival when combined with chemotherapy in the first-line 
treatment of extensive-stage SCLC.
Horn et al. [1] published the results of the IMpower 
133 trial in the “New England Journal of Medicine” 
on 25th September 2018. The trial compared the 
combination of atezolizumab and chemotherapy (con-
sisting of carboplatin AUC 5 on day 1 and etoposide 
100 mg/m2 given on days 1–3 of every 21-day cycle) 
with the same chemotherapy regimen plus placebo in 
patients with histologically or cytologically confirmed 
extensive-stage SCLC. After finishing four cycles of 
induction therapy, patients in both arms continued treat-
ment with atezolizumab or placebo as a maintenance. 
No crossover after progression on placebo was planned. 
The primary endpoints were overall survival and inves-
tigator-assessed progression-free survival (PFS). The 
key secondary endpoints included response rate and 
duration of response. The trial enrolled 403 patients, 
randomised in a 1:1 ratio to both arms. After a median 
follow-up time of 13.9 months, the trial met its primary 
endpoint: median overall survival reached 12.3 months 
(95% confidence interval [CI] 10.8–15.9) in the pa-
tients receiving atezolizumab and 10.3 months (95% 
CI 9.3–11.3) in the patients receiving placebo, which 
resulted in the hazard ratio (HR) for death of 0.70 (95% 
CI 0.54–0.91; p = 0.007). The one-year overall survival 
was 51.7% in the atezolizumab arm and 38.2% in the 
placebo arm. Investigator-assessed PFS was also better 
in the experimental group: 5.2 months (95% CI 4.4–5.6) 
versus 4.3 months (95% CI 4.2–4.5) (HR of 0.77; 95% 
CI 0.62–0.96; p = 0.02). The achieved results were con-
sistent among all analysed subgroups, but with a lower 
benefit from the addition of atezolizumab in patients 
with brain metastases and those below 65 years old. 
In contrast to previously available data, atezolizumab 
improved survival regardless of TMB status, without 
additional benefit in patients with the highest TMB. 
Responses were similar between both arm in terms of 
CR, PR, and SD, with a numerically higher rate of PD 
as the best response in patients receiving atezolizumab. 
Despite the prolongation of OS, median duration of 
response was similar in the experimental and control 
arms (4.2 and 3.9 months, respectively). Rates of ad-
verse events were comparable between both groups, 
with identical rates of treatment-related deaths (1.5% 
in both arms). Immune-related adverse events occurred 
in 39.9% of patients in the atezolizumab arm and 24.5% 
in the placebo arm. Similar rates of patients in both 
groups received prophylaxis cranial irradiation after the 
induction part of the treatment.
The results of the IMpower 133 trial support new 
indications for immunotherapy — first-line treatment 
of extensive-stage SCLC. It is the first improvement in 
the field of SCLC within the last 20 years and has the 
potential to impact daily practice, especially in well-de-
veloped countries. However, the gain obtained with 
atezolizumab is only modest and cannot be conside-
red a true breakthrough from a clinical point of view. 
The described data generate several issues, including 
questions about the role of tumour mutational burden 
in SCLC, regarding differences in the benefit from 
immunotherapy in different age groups and limited ef-
fectiveness in patients with brain metastases. As the rate 
of PD as the best response was numerically higher with 
the combination of atezolizumab and chemotherapy, it 
might be hypothesised that a subgroup of patients in the 
experimental arm were harmed by hyperprogression, 
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One more point for immunotherapy — a combination of atezolizumab  
and chemotherapy in the treatment of small-cell lung cancer
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Expanding armamentarium for systemic treatment of hepatocellular carcinoma 
beyond first line
Hepatocellular carcinoma (HCC) emerges as an 
important oncological challenge, mostly due to its rising 
incidence, even in Western countries. Localised HCC is 
best treated with either surgery or locoregional treatment 
modalities with curative intent. In the case of HCC refrac-
tory to locoregional therapy or in the case of metastatic 
disease, systemic treatment remains the basic modality. 
Classically, HCC was considered a chemotherapy-resis-
tant tumour, with a limited activity of cytotoxic drugs such 
as doxorubicin. Advancements in understanding the mo-
lecular background of HCC, especially the role of vascular 
endothelial growth factor in tumour angiogenesis, led to 
the introduction of targeted therapies. This includes the 
first VEGF tyrosine kinase inhibitor (TKI) registered for 
advanced HCC: sorafenib. However, the benefit from 
TKI is limited only to a subset of patients with HCC and 
is temporary, with an almost inevitable development 
of secondary resistance. This need led to a vast search 
for agents active in second and latter lines of systemic 
treatment, with immunomodulating drugs and novel 
TKI being the most promising options. Cabozantinib, 
a representative of a novel generation of TKIs, inhibits 
not only kinases associated with VEGF, but also kinases 
associated with AXL and MET, which are responsible for 
a TKI resistance in pre-clinical models. Recently, several 
new systemic therapies for HCC became available, with 
the latest addition of cabozantinib in the second line.
The data from a phase 3 randomised trial evaluating 
activity of cabozantinib in previously treated patients 
with hepatocellular carcinoma were published on 5th 
July 2018 in the "New England Journal of Medicine" 
by Abou-Alfa et al. [2]. The trial included patients with 
a prior exposure to sorafenib, who received no more 
than two lines of systemic therapy and had Child-Pugh 
class A liver function. Patients were randomised in 
a 2:1 ratio to either cabozantinib at a dose of 60 mg 
daily orally or matched placebo. The primary endpoint 
was overall survival, with the secondary endpoints of 
progression-free survival and objective response rate. 
The trial included 773 patients, 707 of whom constitut-
ed the intention-to-treat population evaluated in the 
aforementioned article. The primary endpoint was met, 
with a median OS of 10.2 months (95% CI 9.1–12.0) in 
the cabozantinib arm and 8.0 months (95% CI 6.8–9.4) 
in the placebo arm, with an HR of 0.76 (95% CI 0.63– 
–0.92; p = 0.005). The median PFS was also significantly 
longer in patients receiving cabozantinib (5.2 months; 
95% CI 4.0–5.5) compared to patients receiving placebo 
(1.9 months; 95% CI 1.9–1.9), with an HR of 0.44 (95% 
CI 0.36–0.52; p < 0.001). Objective response rate and 
disease control rate were also higher in the cabozantinib 
arm. Improvement in PFS was consistent in all analysed 
subgroups, but the benefit in OS seemed to be limited in 
patients from the Asian region, without extrahepatic me-
tastases, and in those with HCV as an aetiological factor 
of HCC. On the other hand, patients treated previously 
with only sorafenib had better numerical benefit from 
cabozantinib (median OS 11.3 vs. 7.2 months, with HR 
0.70; 95% CI 0.55–0.88). In safety analysis, patients re-
ceiving cabozantinib had higher rates of any grade adverse 
events (99% vs. 92%), grade 3 and 4 events (68% vs. 36%) 
and serious adverse events (50% vs. 37%). The most com-
mon grade 3 and 4 toxicities associated with cabozantinib 
were palmar-plantar erythrodysesthesia, hypertension, 
increased aspartate aminotransferase levels, fatigue, and 
diarrhoea, a profile similar to previously described in pa-
tients treated with cabozantinib. Adverse events leading 
death occurred in six patients receiving cabozantinib and 
in one patient receiving placebo. Results of quality-of-life 
evaluation were not reported in the article.
The presented results establish cabozantinib, along 
with regorafenib, as a standard of care in sorafenib-resis-
tant HCC. An immune checkpoint inhibitor, nivolumab, 
was registered in this setting by the Food and Drug 
Administration (FDA) based on a phase 1/2 trial, in 
contrast to the phase 3 trials of cabozantinib and re-
gorafenib, and therefore should be considered only as 
an option. Within a few years, the armamentarium for 
treatment of HCC expanded significantly. First-line 
treatment now includes lenvatinib, a novel TKI inhibi-
tor that proved non-inferior to sorafenib. Additionally, 
in HCC non-amendable for curative local treatment 
radioembolisation offered only marginally worse re-
sults than sorafenib. Second-line treatment, previously 
non-existent or limited to cytotoxic chemotherapy, was 
improved by the addition of regorafenib, cabozantinib, 
and nivolumab. We await results from late-phase trials 
of immunotherapy, both in the salvage setting and in 
first-line treatment, because this modality offers hope 
for significantly improved long-term survival. 
a phenomenon related to immune checkpoint therapy. 
Nevertheless, IMpower 133 is proof of the concept that 
patients with SCLC derive benefit from immunotherapy. 
Further research is undoubtedly needed, especially in 
the search for potential biomarkers that could improve 
patient selection, because combinational chemoimmu-
notherapy will generate a significant financial burden. 
The extension of overall survival, albeit limited, is the 
first improvement in SCLC in decades and brings expec-
tations for further, hopefully more profound, progress.
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Non-metastatic castration-resistant prostate cancer — a challenging disease with 
novel treatment options
As with most types of cancer, recent years brought 
significant improvement in the treatment of prostate 
cancer. The introduction of novel drugs modulating 
hormonal signalling, abiraterone and enzalutamide, 
revolutionised the treatment of metastatic castration-re-
sistant prostate cancer. The addition of docetaxel or 
abiraterone to hormonal treatment in metastatic castra-
tion-sensitive prostate cancer resulted in a tremendous 
gain in overall survival. Prostate cancer became a truly 
chronic disease, with median overall survival reaching 
50 months in some populations. Despite the advance, 
some clinical situations remain a significant challenge. 
With a broader availability of PSA testing and in-
creasingly aggressive management of locally advanced 
prostate cancer, non-metastatic castration-resistant 
prostate cancer became more common. Lack of good 
quality evidence and difficulties in defining aims of 
therapy provided additional difficulties. Fortunately, 
two recently published trials provided data regarding 
management of patients in this setting.
The first trial data are from the SPARTAN trial, 
published by Smith et al. [3] in the “New England 
Journal of Medicine” on 12th April 2018. This dou-
ble-blinded, randomised, phase 3 clinical trial compared 
apalutamide, a nonsteroidal antiandrogen that acts by 
a direct blockade of androgen receptor, with placebo 
in non-metastatic castration-resistant prostate can-
cer, which had a PSA-doubling time of 10 months or 
less. Apalutamide was given at a daily dose of 240 mg per 
day. Androgen-deprivation therapy (either by a bilateral 
orchidectomy or with gonadotropin-releasing hormone 
analogue agonist or antagonist) was required during the 
trial. The primary endpoint was metastasis-free survival 
and secondary end points included: time to metastasis, 
progression-free survival, time to symptomatic progres-
sion, and overall survival. The trial accrued 1207 pa-
tients, randomised in a 2:1 ratio to either apalutamide or 
placebo. After a median follow-up time of 20.3 months, 
the primary endpoint was met. Median metastasis-free 
survival reached 40.5 months in patients receiving apa-
lutamide and 16.2 months in patients receiving placebo, 
with an HR for metastasis or death of 0.28 (95% CI 
0.23–0.35; p < 0.001). Results were consistent in all 
analysed subgroups. This result led to the recommen-
dation of the monitoring committee to unblind the trial 
and offer apalutamide treatment to patients receiving 
placebo. Secondary endpoints of time to metastasis, 
progression-free survival, and time to symptomatic 
progression were significantly better in the apalutamide 
arm compared to the placebo arm (p < 0.001 for all). 
Due to the data immaturity, the difference in OS have 
not reached significance, but a trend toward improve-
ment in OS was seen with apalutamide (p = 0.07). In 
safety analysis, grade 3 and 4 adverse events were more 
commonly observed in the apalutamide arm than in 
the placebo arm (45.1% vs. 34.2%, respectively), but 
the rate of serious adverse events (24.8% vs. 23.1%, 
respectively) and adverse events leading to treatment 
discontinuation (10.6% vs. 7.0%, respectively) were 
similar between both arms. The most common adverse 
events attributed to apalutamide were fatigue (30.4% 
vs. 21.1%), rash (23.8% vs. 5.5%), falls (15.6% vs. 9.0%), 
fractures (11.7% vs. 6.5%), and hypothyroidism (8.1% 
vs. 2%). Adverse events leading to death were observed 
in six patients receiving apalutamide and in one patient 
receiving placebo.
The second study, the PROSPER trial, was pub-
lished by Hussain et al. [4] in the “New England Journal 
of Medicine” on 28th June 2018. The PROSPER trial was 
a phase 3, double-blinded, placebo-controlled clinical 
trial evaluating enzalutamide, an antiandrogen directly 
blocking androgen receptor, in patients with non-met-
astatic castration-resistant prostate cancer with a PSA 
doubling time of less than 10 months and PSA level of at 
least 2 ng/ml. The primary endpoint of the trial was me-
tastasis-free survival, and secondary endpoints included 
time to PSA progression, PSA response rate, time to the 
subsequent therapy initiation, quality-of-life (FACT-P 
score), overall survival, and safety. The PROSPER trial 
enrolled 1401 patients, randomised in a 2:1 ratio to ei-
ther enzalutamide (given at a standard dose of 160 mg 
daily) or matched placebo. The primary endpoint was 
met, with the median metastasis-free survival reaching 
36.6 months in the enzalutamide arm and 14.7 months 
in the placebo arm (after a median follow-up time of 
18.5 months and 15.1 months, respectively). This result-
ed in an HR for radiographic progression or death of 
0.29 (95% CI 0.24–0.35; p < 0.001). Achieved effects 
were comparable in all subgroups analysed. From the 
secondary endpoints, the time to PSA progression and 
the time to subsequent therapy initiation were signifi-
cantly better in the enzalutamide arm (p < 0.001 for 
both). Median overall survival was not been reached 
in either arm, without significant differences between 
arms (HR for death of 0.8; 95% CI 0.58–1.09; p = 0.15). 
Results of quality-of-life assessment were comparable 
between both arms, including similar time to score 
degradation. Rate of grade 3 or worse adverse events 
and rate of serious adverse events were numerically 
higher in patients receiving enzalutamide (31% and 
24%, respectively) when compared to patients receiving 
placebo (23% and 18%, respectively). More fatigue, 
hypertension, major cardiovascular events, and mental 
impairment disorders were observed in the experimental 
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arm. Adverse events leading to death occurred more 
often in the enzalutamide group (3% vs. 1%; 32 events 
and 3 events). 
Both trials, SPARTAN and PROSPER, provide 
good quality data supporting treatment of non-meta-
static castration-resistant prostate cancer with novel 
antiandrogens. Apalutamide and enzalutamide were 
proved to prolong metastasis-free survival, showed 
activity in this setting, and can be considered an option 
of care. However, because both trials have not yet 
provided evidence of OS prolongation and both drugs 
are associated with an increased risk of adverse events, 
every decision regarding their implementation should 
be carefully deliberated. Fortunately, the results of the 
SPARTANT trial suggest a trend towards improvement 
of OS, and further data might provide more arguments 
for the usage of novel antiandrogens in the non-meta-
static castration-resistant prostate cancer setting. 
Hunting down breast cancer harbouring mutated BRCA1/2 genes
Breast cancer associated with BRCA1/2 gene mu-
tations is a significant burden in modern oncology, 
mostly due to the hereditary nature of this disease. 
Additionally, the presence of BRCA1/2 mutations 
in cancer cells often corelates with aggressive tri-
ple-negative immunophenotype, with a worse prog-
nosis even at early stages. Generally, it is estimated 
that about 5–10% of breast cancers harbour mutated 
BRCA1/2 genes, with prevalence varying deeply be-
tween different populations. Beside germinal muta-
tions, about 3% of all breast cancer patients harbour 
somatic BRCA1/2 mutations and are not hereditary. 
Since their identification, BRCA1/2 genes are consid-
ered a promising therapeutic target. Poly(adenosine 
diphosphate-ribose) polymerase inhibitors (PARPi), 
initially registered for the treatment of germline 
BRCA mutated ovarian cancer, are active in the 
treatment of metastatic breast cancer harbouring 
germline BRCA mutations. This was confirmed in 
a phase 3 trial comparing olaparib with the physi-
cians’ choice of chemotherapy. Now, another PARPi 
showed superiority over cytotoxic chemotherapy in 
patients with metastatic germline BRCA1/2 mutated 
breast cancer.
Litton et al. [5] published on 23rd August 2018 in 
the “New England Journal of Medicine” the results of 
a phase 3 trial comparing talazoparib, a PARPi, with 
standard single-agent chemotherapy (capecitabine, 
eribulin, gemcitabine, or vinorelbine) in patients 
with breast cancer harbouring germline BRCA mu-
tations. Talazoparib was administered orally at 1 mg 
daily in a continuous manner. The primary endpoint 
was progression-free survival, assessed by an indepen-
dent central review. The secondary endpoint includ-
ed: overall survival, objective response rate, clinical 
benefit rate at 24 weeks, and duration of response. 
The trial included quality-of-life analysis through EO-
RTC QLQ-C30 and QLQ-BR23 questionnaires. The 
trial accrued 431 patients, randomised in 2:1 ratio to 
either the experimental arm with talazoparib or the 
standard arm with chemotherapy. After a median 
follow-up of 11.2 months, the trial met its primary 
endpoint, with an improvement of median PFS to 
8.6 months (95% CI 7.2–9.3) in the talazoparib arm 
from 5.6 months (95% CI 4.2–6.7) in the standard 
arm, with the HR for disease progression or death of 
0.54 (95% CI 0.41–0.71; p < 0.001). The effect was 
consistent across all analysed subgroups, with slightly 
less benefit seen in patients previously treated with 
platinum compounds. At described interim analysis, 
the difference in overall survival between both arms 
did not achieve statistical significance (22.3 months 
[95% CI 18.1–26.2] in patients receiving talazoparib 
vs. 19.5 months [95% CI 16.3–22.4] in patients receiving 
standard chemotherapy) (HR 0.76; 95% CI 0.55–1.06; 
p = 0.11), which might be due to the immaturity of the 
data. The talazoparib group achieved better results in 
response rate (62.6% vs. 27.2%), clinical benefit at 
24 weeks (68.6% vs. 36.1%), and duration of response 
(5.4 months vs. 3.1 months). The rate of serious ad-
verse events (31.8% in patients receiving talazoparib 
and 29.4% in patients receiving chemotherapy) and 
rate of grade 3 and 4 serious adverse events (25.5% 
and 25.4%, respectively) were similar between both 
arms. More haematological grade 3 and 4 adverse events 
were observed with talazoparib (55% vs. 38%), with 
opposing results regarding non-haematological grade 
3 and 4 adverse events (32% vs. 38%). Adverse events 
led to treatment discontinuation in 5.9% of patients 
receiving talazoparib and in 8.7% of patients receiving 
chemotherapy. Significantly better results regarding 
quality of life were seen in the talazoparib arm with 
both QLQ-C30 questionnaire (increase of 3.0 points 
[95% CI 1.2–4.8] vs. –5.4 points [95% CI –8.8 to –2.0; 
p < 0.001]) and QLQ-BR23 (decrease of symptoms of 
–5.1 points [95% CI –6.7 to –3.5] vs. –0.1 points [95% 
CI –2.9–2.6; p = 0.002]).
As a result of the trial, talazoparib joins olaparib as 
a treatment option for patients with metastatic cancer 
harbouring germline BRCA1/2 mutations, providing 
further proof for PARPi activity in this setting. Benefit 
of talazoparib is limited not only to progression-free 
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survival, but comes also with a significant improvement 
in the quality-of-life scores. Additionally, numerical 
improvement in median OS was seen, although this 
requires confirmation as the data mature. Several 
questions remain unanswered, especially considering 
comparison of PARPi and platinum derivatives, because 
cancers with present BRCA1/2 mutations might be more 
sensitive to both PARPi and platinum compounds. Oth-
er questions concern activity of PARPi in breast cancers 
with somatic BRCA1/2 mutations and activity of PARPi 
in BRCA1/2 mutated cancers other than breast cancer. 
Hopefully, further studies will expand the indication for 
PARPi, and more patients will be able to benefit from 
a more personalised therapeutic approach. 
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